3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
4
Nasopharyngeal Carcinoma
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Esophageal Neoplasms
3
Pancreatic Neoplasms
2
Locally Advanced Rectal Cancer
2
Colonic Neoplasms
2
Cervical Cancer Metastatic
2
Breast Neoplasms
2
Adenocarcinoma
2
Turcot syndrome
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Cancer Patients
1
Non-squamous Non-small-cell Lung Cancer
1
Mouth Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Laryngeal Neoplasms
1
Gestational Trophoblastic Disease
1
Esophageal Squamour Cell Cancer
1
Endometrioid Endometrial Cancer
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Primary Liver Cancer
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
camrelizumab
×
1 year
×
Clear all
NCT06215677
2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA
Recruiting
18 enrolled